Research programme: cancer stem cell antibodies - Bioprocessing Technology Institute/Raven biotechnologies
Latest Information Update: 16 Jul 2016
At a glance
- Originator Bioprocessing Technology Institute; Raven biotechnologies
- Class Antibodies; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Apr 2008 Preclinical trials in Cancer in USA (Parenteral)